FDA Clears Updated Ezra Flash AI Software for MRI Scans
The updated AI-enabled software reportedly facilitates enhanced MRI imaging of the brain, abdomen, and pelvis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for updated artificial intelligence (AI) software that bolsters image quality on magnetic resonance imaging (MRI) scans.
Emphasizing noise reduction without sacrificing diagnostic integrity, the Ezra Flash AI software bolsters the quality of MRI scans of the brain, abdomen and pelvis, according to Ezra, the manufacturer of Ezra Flash AI.
In addition to enhanced neuroimaging, the newly FDA-cleared updates for the Ezra Flash AI software may provide visualization with abdominal and pelvic MRI scans, according to Ezra, the developer of the software. (Images courtesy of Ezra.)
The company maintained that the enhanced image quality obtained with Ezra Flash AI will provide greater clarity in MRI interpretation and precise analysis to facilitate a more timely diagnosis.
"The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible," said Daniel K. Sodickson, M.D., Ph.D, the chief scientific advisor at Ezra and chief of innovation in the Department of Radiology at the New York University Grossman School of Medicine. "This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions."
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
